A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G

Chong, J.; Satwi, Sapari; Kuan, Yeh Chunn

doi:10.1016/j.jmii.2010.07.001

Cited by 18 publications

(14 citation statements)

References 6 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a few case reports are available [60,77-80]. Therefore, there is not sufficient evidence to recommend the administration of IVIG to a severe influenza patient.…”

Section: Other Treatmentsmentioning

confidence: 99%

Severe influenza treatment guideline

Choi

Baek

Seo

et al. 2014

Korean J Intern Med

View full text Add to dashboard Cite

“…Only a few case reports are available [60,77-80]. Therefore, there is not sufficient evidence to recommend the administration of IVIG to a severe influenza patient.…”

Section: Other Treatmentsmentioning

confidence: 99%

Severe influenza treatment guideline

Choi

Baek

Seo

et al. 2014

Korean J Intern Med

View full text Add to dashboard Cite

“…These data suggest a potential role for adjunctive IVIG therapy for severe influenza, especially in immunocompromised patients. A case report on a 59-year-old male patient with ARDS due to H1N1pdm09 influenza, who did not respond initially to twice-daily oseltamivir at a dose of 150 mg, described a favorable outcome following the administration of IVIG (Chong et al, 2011). Significant neutralizing activities against influenza A(H2N2) viruses have been observed in lots of human IVIG manufactured from 1993-2010 in Japan (Kubota-Koketsu et al, 2012).…”

Section: Intravenous Immunoglobulin (Ivig) Preparationsmentioning

confidence: 99%

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

2013

View full text Add to dashboard Cite

In addition to neuraminidase inhibitors and other drugs that directly target viral replication, a number of adjunctive and immunomodulatory therapies are currently under evaluation for the treatment of influenza. These novel treatments, which focus either on pathophysiological aspects of influenza virus infection or the neutralization of virus with antibodies, are the subject of this review. Cytokine dysregulation has been observed in patients with severe influenza, such as avian influenza A (H5N1) and pandemic 2009 influenza A (H1N1pdm09) virus infections, but the role of immunomodulatory therapy is unclear, due to lack of data from randomized controlled trials (RCTs). Convalescent plasma appears to be useful as an adjunctive therapy for the treatment of H5N1 and H1N1pdm09 infections. Until lately, data interpretation was limited to case reports and studies of non-randomized design, but a recent RCT found that patients with severe influenza A (H1N1pdm09) who were treated with hyperimmune immunoglobulin from persons who had survived the same disease had a lower peak viral load and lower mortality than controls, providing treatment was begun within 5 days of symptom onset. The efficacy of agents with potential immunomodulating effects, including intravenous immunoglobulin, N-acetylcysteine, acute use of statins, macrolides, peroxisome proliferator-activated receptors agonists, celecoxib and mesalazine, and the role of plasmapheresis and hemoperfusion as rescue therapy, deserve more investigation and where feasible, studies by RCTs. Prospective observational studies have shown that systemic corticosteroids increase morbidity (e.g., secondary infections) and mortality in H1N1pdm09 influenza. This article forms part of a symposium in Antiviral Research on "Treatment of influenza: targeting the virus or the host."

show abstract

“…At this time, specific reports of the use of IVIg in human cases of influenza, while promising, are limited (Luke et al, 2010, Chong et al, 2011, Zhang et al, 2010, Dubnov-Raz et al, 2011). Studies relating to the treatment or prevention of influenza have reported reduced mortality in patients transfused with convalescent human blood products derived from the plasma of individuals who have been infected with the same strain and subsequently recovered (reviewed (Luke et al, 2010, Luke et al, 2006)).…”

Section: Discussionmentioning

confidence: 99%

Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection

Rockman

Lowther

Camuglia³

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

Influenza is a highly contagious, acute, febrile respiratory infection that can have fatal consequences particularly in individuals with chronic illnesses. Sporadic reports suggest that intravenous immunoglobulin (IVIg) may be efficacious in the influenza setting. We investigated the potential of human IVIg to ameliorate influenza infection in ferrets exposed to either the pandemic H1N1/09 virus (pH1N1) or highly pathogenic avian influenza (H5N1). IVIg administered at the time of influenza virus exposure led to a significant reduction in lung viral load following pH1N1 challenge. In the lethal H5N1 model, the majority of animals given IVIg survived challenge in a dose dependent manner. Protection was also afforded by purified F(ab′)2 but not Fc fragments derived from IVIg, supporting a specific antibody-mediated mechanism of protection. We conclude that pre-pandemic IVIg can modulate serious influenza infection-associated mortality and morbidity. IVIg could be useful prophylactically in the event of a pandemic to protect vulnerable population groups and in the critical care setting as a first stage intervention.

show abstract

A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G

Cited by 18 publications

References 6 publications

Severe influenza treatment guideline

Severe influenza treatment guideline

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection

Contact Info

Product

Resources

About